How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

9,239 results for

Age-Related Macular Degeneration

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Optical coherence tomography (OCT) for neovascular age-related macular degeneration as well as diabetic retinopathy with macular oedema

Optical coherence tomography (OCT) for neovascular age-related macular degeneration as well as diabetic retinopathy with macular oedema 1 Translation of the key statement of the final report D15-01 Optische Kohärenztomografie bei neovaskulärer altersbedingter Makuladegeneration sowie beim Makulaödem im Rahmen der diabetischen Retinopathie (Version 1.1; Status: 7 July 2017). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English (...) -language readers. However, solely the German original text is absolutely authoritative and legally binding. Extract IQWiG Reports – Commission No. D15-01 Optical coherence tomography (OCT) for neovascular age-related macular degeneration as well as diabetic retinopathy with macular oedema 1 Extract of final report D15-01 Version 1.1 Optical coherence tomography for maculo- and retinopathy 7 July 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

2. Age-related macular degeneration

Age-related macular degeneration Age-related macular degener Age-related macular degeneration ation NICE guideline Published: 23 January 2018 nice.org.uk/guidance/ng82 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising (...) . Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Age-related macular degeneration (NG82) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 24Contents Contents Overview 4 Who is it for? 4 Recommendations 5 1.1 Classifying age-related macular

2018 National Institute for Health and Clinical Excellence - Clinical Guidelines

3. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. (PubMed)

Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Age-related macular degeneration (AMD) is the most common cause of uncorrectable severe vision loss in people aged 55 years and older in the developed world. Choroidal neovascularization (CNV) secondary to AMD accounts for most cases of AMD-related severe vision loss. Intravitreous injection of anti-vascular endothelial growth factor (anti-VEGF) agents aims to block the growth of abnormal blood vessels

Full Text available with Trip Pro

2019 Cochrane

4. Treatments for dry age-related macular degeneration and Stargardt disease: a systematic review

Treatments for dry age-related macular degeneration and Stargardt disease: a systematic review Treatments for dry age-related macular degeneration and Stargardt disease: a systematic review Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue (...) {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} This review found a lack of treatments of proven efficacy in dry age-related macular degeneration, and no proven treatments for Stargardt disease, but did identify some promising research topics. {{author}} {{($index , , , , , & . Norman Waugh 1, * , Emma Loveman 2 , Jill Colquitt 2 , Pamela Royle 1 , Jian Lee Yeong 3 , Geraldine Hoad 4 , Noemi Lois 3, 5 1 Division of Health Sciences, University of Warwick, Coventry, UK

2018 NIHR HTA programme

5. Implantable miniature telescope (IMT) for vision loss due to end-stage age-related macular degeneration. (PubMed)

Implantable miniature telescope (IMT) for vision loss due to end-stage age-related macular degeneration. Age-related macular degeneration (AMD) causes progressive and irreversible damage to the retina, resulting in loss of central vision. AMD is the third leading cause of irreversible visual impairment worldwide and the leading cause of blindness in industrialized countries. Since AMD is more common in older individuals, the number of affected individuals will increase significantly (...) as the population ages. The implantable miniature telescope (IMT) is an ophthalmic device developed to improve vision in individuals who have lost vision due to AMD. Once implanted, the IMT is used to enlarge objects in the central visual field and focus them onto healthy areas of the retina not affected by AMD, allowing individuals to recognize objects that they otherwise could not see. It is unclear whether and how much the IMT can improve vision in individuals with end-stage AMD.To assess the effectiveness

2018 Cochrane

7. Age-related macular degeneration

Age-related macular degeneration Age-related macular degeneration - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Age-related macular degeneration Last reviewed: February 2019 Last updated: May 2018 Summary Potentially progressive maculopathy. Sudden-onset of blurring or distortion of vision is often the presenting symptom. Characterised by drusen formation, macular pigmentary changes, geographic atrophy (...) , and neovascularisation of the choriocapillaris with exudation. Leading cause of adult blindness in industrialised nations. Typically affects white people aged >55 years. Diagnosis and treatment are highly specialised and involve consultation with a retinal consultant. Definition Age-related macular degeneration (AMD) is a potentially progressive maculopathy. Arnold J. Age related macular degeneration. BMJ Clin Evid. February 2016. http://clinicalevidence.bmj.com/ (last accessed 26 September 2017). http

2018 BMJ Best Practice

8. [Optical coherence tomography (OCT) for neovascular age-related macular degeneration as well as diabetic retinopathy with macular oedema]

[Optical coherence tomography (OCT) for neovascular age-related macular degeneration as well as diabetic retinopathy with macular oedema] Optische kohärenztomografie bei neovaskulärer altersbedingter makuladegeneration sowie beim makulaödem im rahmen der diabetischen retinopathie: abschlussbericht; auftrag D15-01 [Optical coherence tomography (OCT) for neovascular age-related macular degeneration as well as diabetic retinopathy with macular oedema] Optische kohärenztomografie bei neovaskulärer (...) altersbedingter makuladegeneration sowie beim makulaödem im rahmen der diabetischen retinopathie: abschlussbericht; auftrag D15-01 [Optical coherence tomography (OCT) for neovascular age-related macular degeneration as well as diabetic retinopathy with macular oedema] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made

2017 Health Technology Assessment (HTA) Database.

9. Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration. (PubMed)

Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration. It has been proposed that antioxidants may prevent cellular damage in the retina by reacting with free radicals that are produced in the process of light absorption. Higher dietary levels of antioxidant vitamins and minerals may reduce the risk of progression of age-related macular degeneration (AMD).The objective of this review was to assess the effects of antioxidant vitamin or mineral (...) is needed. Supplements containing lutein and zeaxanthin are heavily marketed for people with age-related macular degeneration but our review shows they may have little or no effect on the progression of AMD.

Full Text available with Trip Pro

2017 Cochrane

10. Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration. (PubMed)

Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration. There is inconclusive evidence from observational studies to suggest that people who eat a diet rich in antioxidant vitamins (carotenoids, vitamins C, and E) or minerals (selenium and zinc) may be less likely to develop age-related macular degeneration (AMD).To determine whether or not taking antioxidant vitamin or mineral supplements, or both, prevent the development of AMD.We searched the Cochrane (...) , and clear evidence of benefit is needed before they can be recommended. People with AMD should see the related Cochrane Review on antioxidant vitamin and mineral supplements for slowing the progression of AMD, written by the same review team.

Full Text available with Trip Pro

2017 Cochrane

11. Surgery for cataracts in people with age-related macular degeneration. (PubMed)

Surgery for cataracts in people with age-related macular degeneration. Cataract and age-related macular degeneration (AMD) are common causes of decreased vision that often occur simultaneously in people over age 50. Although cataract surgery is an effective treatment for cataract-induced visual loss, some clinicians suspect that such an intervention may increase the risk of worsening of underlying AMD and thus have deleterious effects on vision.The objective of this review was to evaluate (...) -surgery group versus 0 of 29 participants in the delayed-surgery group at six months (risk ratio 3.21, 95% CI 0.14 to 75.68; 56 participants; very low-certainty evidence). Quality of life was measured using two different questionnaires. Scores on the Impact of Vision Impairment (IVI) questionnaire suggested that the immediate-surgery group fared better regarding vision-related quality of life than the delayed-surgery group at six months (MD in IVI logit scores 1.60, 95% CI 0.61 to 2.59; low-certainty

Full Text available with Trip Pro

2017 Cochrane

12. Association Between Cilioretinal Arteries and Advanced Age-Related Macular Degeneration: Secondary Analysis of the Comparison of Age-Related Macular Degeneration Treatment Trials (CATT). (PubMed)

Association Between Cilioretinal Arteries and Advanced Age-Related Macular Degeneration: Secondary Analysis of the Comparison of Age-Related Macular Degeneration Treatment Trials (CATT). Recent reports suggest that cilioretinal arteries (CRAs) confer protection against developing advanced age-related macular degeneration (AMD).To further characterize the association between the presence of a CRA and incidence of geographic atrophy (GA) or choroidal neovascularization (CNV).This cohort study (...) constituted an ad hoc secondary analysis of data from the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) and was performed at 44 clinical centers in the United States among participants in CATT with CNV in the study eye and without advanced AMD in the fellow eye at baseline. The presence of a CRA was determined by 2 graders, masked to clinical data, using color fundus photographs, red-free fundus photographs, and fluorescein angiography. The proportion with CRAs at baseline

2019 JAMA ophthalmology

13. Aflibercept for neovascular age-related macular degeneration. (PubMed)

Aflibercept for neovascular age-related macular degeneration. Central vision loss caused by age-related macular degeneration (AMD) is the leading cause of blindness among the elderly in developed countries. Neovascular AMD is characterized by choroidal neovascularization (CNV). Growth of new blood vessels in patients with neovascular AMD is driven by a complex process that involves a signal protein called vascular endothelial growth factor A (VEGF-A). Anti-VEGF drugs that block this protein

Full Text available with Trip Pro

2016 Cochrane

14. Statins for age-related macular degeneration. (PubMed)

Statins for age-related macular degeneration. Age-related macular degeneration (AMD) is a progressive, late-onset disorder of the macula affecting central vision. It is the leading cause of blindness in people over 65 years in industrialized countries. Recent epidemiologic, genetic, and pathological evidence has shown that AMD shares a number of risk factors with atherosclerosis, leading to the hypothesis that statins may exert protective effects in AMD.The objective of this review

Full Text available with Trip Pro

2016 Cochrane

15. EFFECT OF INTRAOCULAR PRESSURE-LOWERING MEDICATIONS ON NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATMENT OUTCOMES IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENT TRIALS. (PubMed)

EFFECT OF INTRAOCULAR PRESSURE-LOWERING MEDICATIONS ON NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATMENT OUTCOMES IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENT TRIALS. To evaluate the effect of intraocular pressure-lowering medications on treatment outcomes in the Comparison of AMD Treatments Trials.Secondary analysis of Comparison of AMD Treatments Trials data. Medication logs were reviewed for continuous 2-year use of agents that increased aqueous outflow (Group (...) endothelial growth factor therapy for neovascular age-related macular degeneration was associated with a trend toward greater reductions in retinal and total thickness as well as improved visual outcomes over 2 years. A similar effect was not observed to the same extent with agents that increase aqueous outflow. Because of the small sample size and secondary analysis, these findings must be cautiously interpreted and perhaps serve as a basis for future prospective studies.

2018 Retina

16. Development and testing of a patient-derived questionnaire for treatment of neovascular age-related macular degeneration: dimensions of importance in treatment of neovascular age-related macular degeneration. (PubMed)

Development and testing of a patient-derived questionnaire for treatment of neovascular age-related macular degeneration: dimensions of importance in treatment of neovascular age-related macular degeneration. Studies reporting on patient perspectives during treatment of neovascular age-related macular degeneration (nAMD) are limited. Thus, the aim of this study was to develop and test psychometric performance of a patient-derived questionnaire to capture important experiences during

2018 Acta ophthalmologica

17. Ranibizumab or bevacizumab in age-related macular degeneration?

Ranibizumab or bevacizumab in age-related macular degeneration? Prescrire IN ENGLISH - Spotlight ''In the May issue of Prescrire International: Ranibizumab or bevacizumab in AMD?'', 1 May 2016 {1} {1} {1} | | > > > In the May issue of Prescrire International: Ranibizumab or bevacizumab in AMD? Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight (...) In the May issue of Prescrire International: Ranibizumab or bevacizumab in AMD? FREE DOWNLOAD The Italian independent drug bulletin Informazioni sui Farmaci published a review comparing ranibizumab versus bevacizumab for age-related macular degeneration (AMD). Its conclusion differs from that of Prescrire’s review. A letter from Informazioni sui Farmaci's editors and Prescrire's reply explore the various scientific and policy questions surrounding these treatments. Full text available for free download

2016 Prescrire

18. No CFH or ARMS2 Interaction with Omega-3 Fatty Acids, Low versus High Zinc, or β-Carotene versus Lutein and Zeaxanthin on Progression of Age-Related Macular Degeneration in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report No. 18 (PubMed)

No CFH or ARMS2 Interaction with Omega-3 Fatty Acids, Low versus High Zinc, or β-Carotene versus Lutein and Zeaxanthin on Progression of Age-Related Macular Degeneration in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report No. 18 To assess whether genotypes at 2 major loci associated with age-related macular degeneration (AMD), complement factor H (CFH), or age-related maculopathy susceptibility 2 (ARMS2), modify the response to oral nutrients for the treatment of AMD (...) in the Age-Related Eye Disease Study 2 (AREDS2).Post hoc analysis of a randomized trial.White AREDS2 participants.AREDS2 participants (n = 4203) with bilateral large drusen or late AMD in 1 eye were assigned randomly to lutein and zeaxanthin, omega-3 fatty acids, both, or placebo, and most also received the AREDS supplements. A secondary randomization assessed modified AREDS supplements in 4 treatment arms: lower zinc dosage, omission of β-carotene, both, or no modification. To evaluate the progression

2019 Ophthalmology

19. The Association of Aspirin Use with Age-Related Macular Degeneration Progression in the Age-Related Eye Disease Studies: Age-Related Eye Disease Study 2 Report No. 20. (PubMed)

The Association of Aspirin Use with Age-Related Macular Degeneration Progression in the Age-Related Eye Disease Studies: Age-Related Eye Disease Study 2 Report No. 20. To analyze the potential association between aspirin use and progression of age-related macular degeneration (AMD).Two prospective cohort studies within 2 controlled clinical trials of oral supplementation for age-related eye disease.Age-Related Eye Disease Study (AREDS) participants 55 to 80 years of age and AREDS2 participants (...) 50 to 85 years of age.Propensity scores for aspirin use were calculated for AREDS and AREDS2 participants separately by logistic regression. Of the participants without late AMD (geographic atrophy [GA] or neovascular AMD) in either eye at study baseline, aspirin users were matched 1:1 with nonusers by propensity score (separately for AREDS and AREDS2). Proportional hazards regression was performed, adjusting for age, on the matched participants to evaluate associations between aspirin propensity

2019 Ophthalmology

20. Computational modeling of retinal hypoxia and photoreceptor degeneration in patients with age-related macular degeneration. (PubMed)

Computational modeling of retinal hypoxia and photoreceptor degeneration in patients with age-related macular degeneration. Although drusen have long been acknowledged as a primary hallmark of dry age-related macular degeneration (AMD) their role in the disease remains unclear. We hypothesize that drusen accumulation increases the barrier to metabolite transport ultimately resulting in photoreceptor cell death. To investigate this hypothesis, a computational model was developed to evaluate

Full Text available with Trip Pro

2019 PLoS ONE

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>